BPC-157
Also known as: Body Protection Compound-157, Pentadecapeptide BPC 157
BPC-157 is a synthetic gastric-protein-related pentadecapeptide with extensive animal repair research and limited, low-certainty human reports. Its history, preliminary clinical signals, safety unknowns and unapproved status belong alongside the mechanistic interest.
Quick Facts
Identity and chemical form
BPC-157 abbreviates Body Protection Compound-157. The 15-amino-acid sequence is GEPPPGKPADDAGLV, a laboratory-made fragment modeled on a larger protective gastric-juice protein. It is commonly described as cytoprotective rather than as a hormone with one well-defined receptor. The free base has molecular weight 1,419.53 g/mol; acetate forms differ, and an unspecified acetate preparation should not be assigned the free-base value. FDA’s assessment distinguishes those bulk substances, neither an ingredient of an approved drug.
Supporting references: pentadecapeptide; “cytoprotective” agent.
The research and development path
The historical account traces the idea to Predrag Sikiric’s 1975 stress-response lecture at Zagreb, a research team collecting human/animal gastric juice by 1983, and isolation of the 15-residue peptide in 1989. A 2026 STAT profile describes personal and Croatian historical meanings behind the name.
PLIVA began development in 1993, later with Parke-Davis, including animal studies and small ulcerative-colitis investigations in the early 2000s. The second clinical account suggested a favorable but nonsignificant result. The program was shelved after GlaxoSmithKline acquired PLIVA’s institute in 2006, and rights returned to Sikiric in 2009. From around 2010 it spread through forums and research suppliers rather than an ongoing conventional pharmaceutical program. A 2025 review identified 544 articles from 1993–2024, concentrated in relatively few groups. Article counts do not equal independent replications.
Registered oral Phase 1 study NCT02637284 ran around 2015–2016 in Tijuana, Mexico. The cited record has unknown status and no posted published results, so it does not supply independently reported clinical safety findings.
Supporting references: 2026 STAT News profile; 2025 systematic review; NCT02637284; ClinicalTrials.gov; 2025 systematic review.
Preclinical repair pathways
Animal and cell work proposes angiogenesis through VEGFR2–Akt–eNOS and nitric-oxide-related vascular signaling, along with collagen/fibroblast, inflammatory and pain-pathway effects. Tendon-cell work reported increased growth-hormone-receptor expression. Rodent models involve muscle, tendon, ligament, bone and gastrointestinal tissue. In a rat Achilles-transection experiment, tendon strength, elasticity and function improved and the defect was smaller by day 14.
Animal work describes hepatic metabolism, renal clearance and a half-life under 30 minutes. These are not verified human pharmacokinetics and cannot justify a human injection schedule or a precise duration of clinical action.
Supporting references: BPC-157 improved tendon strength, elasticity, and function.
Sources: [11]
Reviews and limited human findings
The 2025 orthopedic/musculoskeletal review included 36 studies, 35 preclinical and one clinical, within its search through June 2024. A 2019 review similarly emphasized rodent healing effects with efficacy still unconfirmed in humans. The retrospective knee-pain report described 12 patients: seven (58%) reported relief longer than six months after one knee injection, without a controlled comparison, effect-size analysis or reported safety data in that account.
The retained 2026 human-evidence review, searching through June 2026, included three uncontrolled reports totaling 30 people across knee pain, bladder symptoms and IV safety. It rated them methodologically poor and very low certainty. Those differing scopes/dates explain why one review’s single human report is not the entire current clinical record.
| Clinical context | Findings and limitations |
|---|---|
| 2005 ulcerative-colitis meeting abstract summarized by FDA | 53 people with mild-to-moderate disease randomized double-blind to 80 mg rectal enemas daily for two weeks; 46 completed. Disease-activity changes numerically favored BPC-157, but FDA’s between-group confidence interval crossed zero. Original abstract access/methods were limited. |
| Two-person IV pilot | No adverse reactions reported through day three, with laboratory/vital changes judged clinically insignificant by the authors; previously exposed adults and tiny, brief observation cannot establish uncommon or chronic harms. |
No adequately completed, published controlled human program establishes general clinical efficacy or long-term safety. The limited rectal trial account deserves recognition, but does not demonstrate oral/subcutaneous benefit, IBS/Crohn’s treatment or a universal gut-healing regimen.
Supporting references: 2019 review.
Sources: [10]
Approval, compounding developments and sport
BPC-157 has no FDA approval or comparable medicine approval established in the reported account. FDA placed it in interim 503A Category 2 in 2023 because of potential significant safety risks. The April 2026 removal followed nomination withdrawal; it did not create a 503A bulks-list or Category 1 entry. The July 23, 2026 advisory committee vote was favorable but nonbinding and did not itself finalize rulemaking or approve a medicine.
The retained October 27 status check found OIRA’s Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94, received October 14 and pending review. A pending record supplies neither effective policy terms nor covered preparations or a dispensing start date. Compounding permission and finished-drug approval are different outcomes.
The 2026 WADA list prohibits BPC-157 at all times under S0, Non-Approved Substances. A positive test can constitute an anti-doping rule violation, and contaminated products also present a risk for tested athletes.
Supporting references: 503A bulk drug substances list; nominators withdrew their nominations; Pharmacy Compounding Advisory Committee voted in favor; prohibited at all times in sport; WADA Prohibited List.
BPC-157 versus TB-500
Both are unapproved research peptides commonly discussed in recovery and sports, but their identities and evidence are different.
| Feature | BPC-157 | TB-500 |
|---|---|---|
| Origin | Gastric-protein-related synthetic fragment | Synthetic fragment of thymosin beta-4 |
| Proposed mechanism | Broad cytoprotective/vascular-repair pathways | Actin-related cell-movement pathways |
| Animal emphasis | Gastrointestinal and connective-tissue models | Wound and cardiac contexts |
| Sporting category | WADA S0 | WADA S2 |
Full-length thymosin beta-4 findings should not automatically be assigned to its TB-500 fragment. Neither has an established controlled human efficacy program supporting a general recovery protocol. The often-promoted Wolverine combination has no proven benefit or safety merely because its components have different hypotheses.
Dosing and safety limits
No validated universal human dose, dilution volume, storage expiry or cycle follows from animal amounts, vendor-vial directions or small reports. Study-specific rectal and IV exposures are not interchangeable consumer instructions.
FDA identifies immunogenicity, peptide impurities, characterization problems and inadequate route-specific safety information. Its briefing discusses clotting/liver-related animal signals and adverse-event reports with uncertain attribution; those do not establish human incidence or causation. Favorable brief observations and negative animal genotoxicity findings do not settle long-term, reproductive or combination safety. Uncontrolled symptom improvement also cannot separate drug effects from other treatment, natural recovery or reporting bias.
References and further reading
This reference draws on Superpower’s Peptide Library and the research linked below. Peptide Dossier’s editorial team adapted and integrated the material on .
- 10.3390/ijms27062876Identity and chemical formCited in: Identity and chemical form
- 10.3390/ph18060928Identity and chemical formCited in: Identity and chemical form
- statnews.comThe research and development pathCited in: The research and development path
- 10.1177/15563316251355551The research and development pathCited in: The research and development path
- clinicaltrials.govThe research and development pathCited in: The research and development path
- fda.govApproval, compounding developments and sportCited in: Approval, compounding developments and sport
- fda.govApproval, compounding developments and sportCited in: Approval, compounding developments and sport
- statnews.comApproval, compounding developments and sportCited in: Approval, compounding developments and sport
- usada.orgApproval, compounding developments and sportCited in: Approval, compounding developments and sport
- 10.1007/s00441-019-03016-8Reviews and limited human findingsCited in: Reviews and limited human findings
- pubmed.ncbi.nlm.nih.govPreclinical repair pathwaysCited in: Preclinical repair pathways
- ClinicalTrials.govThe research and development pathCited in: The research and development path
- pubmed.ncbi.nlm.nih.govThe research and development pathCited in: The research and development path
- wada-ama.orgApproval, compounding developments and sportCited in: Approval, compounding developments and sport
- pubmed.ncbi.nlm.nih.gov — additional reading
- www.fda.gov — additional reading
- innovisionhm.com — additional reading
- www.reginfo.gov — additional reading
Frequently Asked Questions About BPC-157
Small uncontrolled human reports describe improvements, while a limited rectal ulcerative-colitis trial account did not establish clear between-group superiority. The 2026 review rated its included uncontrolled evidence very low certainty. These findings support further study rather than a reliable general treatment effect.
The reviewed human evidence does not establish a validated treatment regimen. A universal dose, dilution volume or post-mixing expiry cannot be inferred for every product.
No. Animal findings help develop hypotheses, while human safety requires adequate clinical evidence. Small reports cannot rule out uncommon or long-term harms.
No. The described Category 2 withdrawal and favorable advisory vote did not create finished-drug approval or a finalized 503A listing. The later OIRA policy record was pending, without effective dispensing terms established.
No. Research-vendor products are outside the regulated prescription-product framework described here. A listing, certificate or clinician endorsement does not substitute for permitted ingredient status and appropriate pharmaceutical quality.
The regulatory account does not identify a qualifying 503A bulks-list or Category 1 entry. Advisory recommendations and pending policy review are separate from an effective patient-specific dispensing pathway.
Animal work examines gastric mucosal protection, tendon/ligament and wound repair, vascular signaling and connective-tissue responses. Human observations are small and low certainty, with a limited rectal-colitis trial account rather than established broad treatment efficacy.
BPC-157 is gastric-protein-related; TB-500 is a thymosin beta-4 fragment with different sequence and actin-related hypotheses. Both are prohibited in sport under different WADA categories, and neither has a validated general recovery protocol.
BPC-157 is prohibited at all times under the 2026 S0 category. Athletes subject to testing risk an anti-doping violation from exposure, including potentially contaminated products.
No. Section 503A requires a permitted ingredient pathway; a research product or marketing label does not establish that requirement, sterility or FDA medicine approval.
Related Peptides
Continue exploring BPC-157
- BPC-157 + TB-500 Blend: Evidence & Combination Questions [2026]Guide
- BPC-157 Before & After: Evidence & Results Timelines [2026]Guide
- BPC-157 Benefits: Healing & Health [2026 Guide]Guide
- BPC-157 Capsules: Oral Guide & Bioavailability [2026]Guide
- BPC-157 Dosage Calculator & Guide [2026]Tool
- BPC-157 Dosage Guide: Protocols for Healing and Recovery [2026]Guide
- BPC-157 FDA Status 2026: Is It Approved? (PCAC Voted Yes to Compounding)Guide
- BPC-157 for Gut Healing: Mechanism, Dosing, Evidence [2026]Guide
Our library review is ongoing. Read how we evaluate evidence or report a correction.
Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.